Abstract

Background: Breast cancer (BC) is the most frequently occurring and life-threatening malignant tumor in women. The evidence that link diabetes biomarkers and BC is highly controversial. Aims: To evaluate the diabetes biomarkers in BC-patients according to type of treatment exposure, BC severity and menopausal status. Methods: A total of 396 BC patients aged 25-65 years attending BC clinics were evaluated. The experimental design permitted to include 134 newly-diagnosed BC patients who were not exposed to any type of interventions and 262 recently-diagnosed BC patients (up to three months). Recently group member were sub-divided in two sub-groups to control exposure to chemotherapy. The patients were further divided according to BC stages and postmenopausal status. Diabetes biomarker consisted of FBG, C-peptide and HOMA-IR. Results: The high FBG was more prevalent in advance (24.1%) than early (10.6%) stage BC. Compared with premenopausal BC patients, postmenopausal BC patients had higher prevalence of abnormal FBG (21.0% vs. 11.1%). The differences were also significant in the mean of FBG (103.0 ± 1.5 vs. 89.0 ± 0.0 mg/dl). In postmenopausal BC patients, FBG was higher in the recently-diagnosed whom expose to treatments including chemotherapy (106.5 ± 1.7 mg/dl vs. 126.2 ± 1.2 mmHg) compared to the newly-diagnosed group whom not yet expose to any kind of treatment interventions. Conclusion: Diabetes was prevalent among BC patients and it was higher in postmenopause and advanced stage BC women. The burden of diabetes on treatment expose BC women tend to be high and warrants closer attention by health care provider to improved outcomes after diagnosis and treatment exposure.